| Prostacyclin biosynthesis in essential hypertension before and during treatment. | |
| | |
MedLine Citation:
|
PMID: 8642189 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Protacyclin biosynthesis was investigated in 133 untreated newly diagnosed patients with uncomplicated essential hypertension. Urinary excretion of 6-oxo-prostaglandin F1 alpha and of 2,3-dinor-6-oxo-prostaglandin F1 alpha, stable breakdown products of prostacyclin, was measured following a 1 month run-in period. To determine whether lowering blood pressure (BP) influenced prostacyclin biosynthesis, 106 consenting patients with diastolic pressure 90-120 mm Hg were allocated randomly to treatment with bendrofluazide, metoprolol, quinapril or amlodipine in an open parallel group design. Dose was increased to reduce diastolic arterial pressure to <90 mm Hg. Terazosin was added if this target BP was not achieved, and its dose increased if necessary. Urinary excretion rates of prostaglandins were measured after 1 year in patients in whom the target diastolic pressure was achieved. Mean arterial pressure varied from 106-168 mm Hg in untreated patients and excretion of both prostacyclin-derived products varied from <5 to >350 ng/g creatinine. Arterial pressure and prostaglandin excretion were not significantly correlated. In 57 patients in whom target pressure was achieved, BP before treatment was 166 +/- 2/100 +/- 1 at baseline and 144 +/- 2/86 +/- 1 mm Hg at 1 year. Excretion rates of each prostacyclin-derived product were similar before treatment and at 1 year, with no significant differences between the drugs. These findings do not support the hypothesis that deficient prostacyclin biosynthesis contributes to the pathogenesis of essential hypertension, or that increased prostacyclin biosynthesis plays a part in the response to treatment with antihypertensive medication. |
| | |
Authors:
|
J M Ritter; S E Brett; J D Woods; N Benjamin; P D Stratton; S E Barrow |
Related Documents
:
|
9893219 - The effects of endurance exercise training on ambulatory blood pressure in normotensive... 15839719 - Hypertension in the elderly: a japanese perspective. 17998769 - Bedtime administration of cilnidipine controls morning hypertension. 15107009 - Effects of exercise, diet and weight loss on high blood pressure. 20409859 - A specific training on hypertension guidelines improves blood pressure control by more ... 11272959 - Assessment of blood pressure discrepancies in third-trimester hypertensive gravidas. 16224079 - Time trends of ischemic stroke incidence and mortality in patients diagnosed with first... 2750839 - Low intraocular pressure and postural changes in intraocular pressure in patients with ... 21091269 - Clevidipine for severe hypertension in patients with renal dysfunction: a velocity tria... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of human hypertension Volume: 10 ISSN: 0950-9240 ISO Abbreviation: J Hum Hypertens Publication Date: 1996 Jan |
Date Detail:
|
Created Date: 1996-07-17 Completed Date: 1996-07-17 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8811625 Medline TA: J Hum Hypertens Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 37-42 Citation Subset: IM |
Affiliation:
|
Department of Clinical Pharmacology, UMDS, Guy's Hospital, London, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
6-Ketoprostaglandin F1 alpha
/
analogs & derivatives,
urine Adult Aged Amlodipine / therapeutic use Antihypertensive Agents / therapeutic use* Bendroflumethiazide / therapeutic use Epoprostenol / biosynthesis* Female Humans Hypertension / drug therapy*, etiology, metabolism* Isoquinolines / therapeutic use Male Metoprolol / therapeutic use Middle Aged Tetrahydroisoquinolines* Thromboxane A2 / metabolism Thromboxane B2 / urine |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Isoquinolines; 0/Tetrahydroisoquinolines; 35121-78-9/Epoprostenol; 37350-58-6/Metoprolol; 54397-85-2/Thromboxane B2; 57576-52-0/Thromboxane A2; 58962-34-8/6-Ketoprostaglandin F1 alpha; 64700-71-6/2,3-dinor-6-ketoprostaglandin F1alpha; 73-48-3/Bendroflumethiazide; 82586-55-8/quinapril; 88150-42-9/Amlodipine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Angiotensin converting enzyme gene I/D polymorphism, blood pressure and the renin-angiotensin system...
Next Document: Heart rate variability before sudden blood pressure elevations or complex cardiac arrhythmias in pha...